News of the Day

Fee 'crunch' for smaller companies and patient populations February 20, 2019

Smaller companies are raising specific concerns about the new PBS and vaccine cost recovery arrangements.

BMS' Davide Piras: The 'challenge' in Australia is not 'dramatically different' February 18, 2019

Davide Piras has a truly global role for Bristol-Myers Squibb, leading the company's business in Europe, Canada and Australia while living in the US.

Is this an evidence-based system? February 15, 2019

What would stop companies bypassing the TGA and presenting new clinical evidence supporting use in new indications directly to the PBAC?

Offer a reduction and we will be more 'receptive' February 14, 2019

The Department of Health denies it has capped the size of rebates it will accept under special pricing arrangements but is openly telling companies it wants more.

Companies paying the 'price' of supply chain payment failure February 13, 2019

Companies are increasingly concerned over the push to reduce published prices and even eliminate some special pricing arrangements.

Government should 'delay and reconsider' R&D tax cut February 12, 2019

A parliamentary inquiry led by Liberal Senator Jane Hume has recommended the government reconsider its reforms of the R&D Tax Incentive.

PD-L1 simplification: Is it a therapeutic group? February 11, 2019

A single simplified listing for the PDL1 inhibitor immunotherapies in lung cancer could secure the government a lower price and create the basis for their expanded use as combination therapy.

Industry looking to push 'comparator' reform February 8, 2019

This 'comparator' issue has been compounded in recent years by multiple rounds of pricing reform that has delivered the government substantial policy-driven price reductions.

NZ PM: PBS comparisons are unfair February 7, 2019

The New Zealand prime minister did not explain why she thought some comparisons showing a huge gulf between the number of new cancer medicines funded by PHARMAC and the PBS are unfair.

Department calls PD-L1 lung cancer meeting February 6, 2019

The Department of Health wrote to stakeholders earlier this week confirming plans for Friday's meeting, with materials, and imposing strict confidentiality requirements.

PBS fee spike driven by 'timely' modelling change February 4, 2019

The Department of Health decided to change how it modelled the cost of PBS listings and doubled its estimate from $15 million to over $30 million - just when the industry agreed it might be willing to pay more.

AZ's Pascal Soriot: 'My Australia and the new AstraZeneca' January 31, 2019

In the first of a two-part interview, AZ CEO Pascal Soriot discusses the new AstraZeneca, his personal affinity with 'home' in Australia and how it 'breaks his heart' governments here have not done more to grow innovative industries.

Latest Video

Most Read

Department of Health reveals facts on key listing stage

BMS' Davide Piras: The 'challenge' in Australia is not 'dramatically different'

Gilead's Rob Hetherington: 'Workplaces have come such a long way'

New deputy chair for Medicines Australia

Fee 'crunch' for smaller companies and patient populations

New Stories

What next for payment reform?

New report calls for greater focus on secondary CV events

Fee 'crunch' for smaller companies and patient populations

Partnership to manage Biomedical Translation Bridge Program

Gilead's Rob Hetherington: 'Workplaces have come such a long way'

Department of Health reveals facts on key listing stage

Response reveals impact of higher price cut threshold

Sign In

Latest Video

Most Read

Department of Health reveals facts on key listing stage

BMS' Davide Piras: The 'challenge' in Australia is not 'dramatically different'

Gilead's Rob Hetherington: 'Workplaces have come such a long way'

New deputy chair for Medicines Australia

Fee 'crunch' for smaller companies and patient populations

Follow Us

New Stories

What next for payment reform?

New report calls for greater focus on secondary CV events

Fee 'crunch' for smaller companies and patient populations

Partnership to manage Biomedical Translation Bridge Program

Gilead's Rob Hetherington: 'Workplaces have come such a long way'

Department of Health reveals facts on key listing stage

Response reveals impact of higher price cut threshold